Presentation is loading. Please wait.

Presentation is loading. Please wait.

Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.

Published byAntony Jennings Modified over 6 years ago

Similar presentations

Presentation on theme: "Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria."— Presentation transcript:

1 Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria. From: Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, Tanzania Clin Infect Dis. 2005;41(8): doi: /444460 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

2 Figure 1 Flow of patients through the study
Figure 1 Flow of patients through the study. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine. From: Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, Tanzania Clin Infect Dis. 2005;41(8): doi: /444460 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

3 Table 2 Falciparum malaria cure rates and likelihood-of-cure analyses associated with receipt of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL). From: Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, Tanzania Clin Infect Dis. 2005;41(8): doi: /444460 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

4 Figure 2 Parasite clearance during the first 3 days of the follow-up period, revealed as the percentage of patients with parasitemia. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine. Bars, 95% CIs. From: Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, Tanzania Clin Infect Dis. 2005;41(8): doi: /444460 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

5 Figure 3 Fever clearance during the first 7 days of the follow-up period, revealed as the percentage of patients with a temperature of ⩾37.5°C. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine. Bars, 95% CIs. From: Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, Tanzania Clin Infect Dis. 2005;41(8): doi: /444460 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

6 Table 3 Proportions of Plasmodium falciparum harboring P
Table 3 Proportions of Plasmodium falciparum harboring P. falciparum multidrug resistance gene 1 (pfmdr1) 86N at baseline and during breakthrough infection. From: Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, Tanzania Clin Infect Dis. 2005;41(8): doi: /444460 Clin Infect Dis | © 2005 by the Infectious Diseases Society of America

Download ppt "Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria."

Similar presentations

Malaria treatment (Current WHO recommendations & guidelines)

Malaria treatment (Current WHO recommendations & guidelines)
Malaria treatment. Dr abdulrahman al shaikh.. Introduction. 1-2.7 million patients died because of malaria every year. Most deaths due to Plasmodium Falciparum.

Malaria treatment. Dr abdulrahman al shaikh.. Introduction million patients died because of malaria every year. Most deaths due to Plasmodium Falciparum.
Drug-drug interaction Satellite Workshop

Drug-drug interaction Satellite Workshop
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.

Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
history 1 ½ y boy Fever –2 weeks –Intermittent –39.5 –Chills and rigor –sweating.

history 1 ½ y boy Fever –2 weeks –Intermittent –39.5 –Chills and rigor –sweating.
Malaria pan-R Malaria cassette. Agenda Disease overview Infectious agents Diagnosis pan-R Malaria cassette: specifications Conclusion.

Malaria pan-R Malaria cassette. Agenda Disease overview Infectious agents Diagnosis pan-R Malaria cassette: specifications Conclusion.
AMI -RAVREDA – USAID Project report, Colombia March 2009 Preliminary results on efficacy and Safety of Coartem ® on the treatment of Acute Uncomplicated.

AMI -RAVREDA – USAID Project report, Colombia March 2009 Preliminary results on efficacy and Safety of Coartem ® on the treatment of Acute Uncomplicated.
Is antimalarial treatment in pregnant women as effective as that in non- pregnant women? Elizabeth Juma, Rashid Aman, Florence Oloo, Bernhards Ogutu Centre.

Is antimalarial treatment in pregnant women as effective as that in non- pregnant women? Elizabeth Juma, Rashid Aman, Florence Oloo, Bernhards Ogutu Centre.
Homework 1 Part 2. Drug Resistance and Malaria Download “Drug Resistance and Malaria” by Peter Bloland, published by the World Health Organization:

Homework 1 Part 2. Drug Resistance and Malaria Download “Drug Resistance and Malaria” by Peter Bloland, published by the World Health Organization:
Antimalarial Drugs.

Antimalarial Drugs.
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Table 1. Baseline Characteristics of the 36,636 Study Subjects

Table 1. Baseline Characteristics of the 36,636 Study Subjects
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam  Mallika Imwong, Tran T Hien, Nguyen T Thuy-Nhien, Arjen M Dondorp,

Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam  Mallika Imwong, Tran T Hien, Nguyen T Thuy-Nhien, Arjen M Dondorp,
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Malaria Prevention & Treatment in Pregnancy

Malaria Prevention & Treatment in Pregnancy

Similar presentations

Ads by Google